

Silvana Del Vecchio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5012787/publications.pdf>

Version: 2024-02-01

71
papers

2,220
citations

257450

24
h-index

233421

45
g-index

71
all docs

71
docs citations

71
times ranked

2695
citing authors

#	ARTICLE	IF	CITATIONS
1	PET-Based Volumetric Biomarkers for Risk Stratification of Non-Small Cell Lung Cancer Patients. <i>Diagnostics</i> , 2021, 11, 210.	2.6	14
2	A Reversible Shift of Driver Dependence from EGFR to Notch1 in Non-Small Cell Lung Cancer as a Cause of Resistance to Tyrosine Kinase Inhibitors. <i>Cancers</i> , 2021, 13, 2022.	3.7	5
3	Non-Canonical Role of PDK1 as a Negative Regulator of Apoptosis through Macromolecular Complexes Assembly at the ER-Mitochondria Interface in Oncogene-Driven NSCLC. <i>Cancers</i> , 2021, 13, 4133.	3.7	5
4	Distribution of Mediastinal Lesions Across Multi-Institutional, International, Radiology Databases. <i>Journal of Thoracic Oncology</i> , 2020, 15, 568-579.	1.1	47
5	Visual and volumetric parameters by 18F-FDG-PET/CT: a head to head comparison for the prediction of outcome in patients with multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 127-135.	1.8	18
6	The Emerging Role of Neutrophil Extracellular Traps (NETs) in Tumor Progression and Metastasis. <i>Frontiers in Immunology</i> , 2020, 11, 1749.	4.8	243
7	Breast Tumor Cell Invasion and Pro-Invasive Activity of Cancer-Associated Fibroblasts Co-Targeted by Novel Urokinase-Derived Decapeptides. <i>Cancers</i> , 2020, 12, 2404.	3.7	4
8	Brain Metastases Unresponsive to Immunotherapy Detected by 18F-FDG-PET/CT in a Patient with Melanoma. <i>Diagnostics</i> , 2020, 10, 410.	2.6	5
9	Preclinical imaging for targeting cancer immune evasion. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 186-193.	0.7	1
10	2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography in primary extranodal lymphomas: treatment response evaluation and prognosis. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 219-225.	0.7	0
11	Coordinate Modulation of Glycolytic Enzymes and OXPHOS by Imatinib in BCR-ABL Driven Chronic Myelogenous Leukemia Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3134.	4.1	20
12	Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer. <i>Annals of Nuclear Medicine</i> , 2019, 33, 937-944.	2.2	35
13	PET/CT in radiation oncology. <i>Seminars in Oncology</i> , 2019, 46, 202-209.	2.2	60
14	Preclinical Imaging in Targeted Cancer Therapies. <i>Seminars in Nuclear Medicine</i> , 2019, 49, 369-381.	4.6	2
15	Inositol Trisphosphate Receptor Type 3-mediated Enhancement of EGFR and MET Cotargeting Efficacy in Non-Small Cell Lung Cancer Detected by 18F-fluorothymidine. <i>Clinical Cancer Research</i> , 2018, 24, 3126-3136.	7.0	15
16	Imaging of immunotherapy response in non-small cell lung cancer: challenges and perspectives. <i>Clinical and Translational Imaging</i> , 2018, 6, 483-485.	2.1	8
17	Translational molecular imaging in exocrine pancreatic cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2442-2455.	6.4	17
18	Performance of FDG-PET/CT in solitary pulmonary nodule based on pre-test likelihood of malignancy: results from the ITALIAN retrospective multicenter trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1898-1907.	6.4	17

#	ARTICLE	IF	CITATIONS
19	Risk-related 18F-FDG PET/CT and new diagnostic strategies in patients with solitary pulmonary nodule: the ITALIAN multicenter trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1908-1914.	6.4	12
20	Neutrophil Extracellular Traps as an Adhesion Substrate for Different Tumor Cells Expressing RGD-Binding Integrins. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2350.	4.1	47
21	The new era of cancer immunotherapy: what can molecular imaging do to help?. <i>Clinical and Translational Imaging</i> , 2017, 5, 299-301.	2.1	8
22	Evaluation of metabolic response with 18F-FDG PET-CT in patients with advanced or recurrent thymic epithelial tumors. <i>Cancer Imaging</i> , 2017, 17, 10.	2.8	7
23	Integrin-dependent cell adhesion to neutrophil extracellular traps through engagement of fibronectin in neutrophil-like cells. <i>PLoS ONE</i> , 2017, 12, e0171362.	2.5	38
24	Preclinical imaging in oncology: advances and perspectives. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 61, 33-47.	0.7	0
25	Detection of Leptomeningeal Involvement by 18F-FDG-PET/CT in a Patient With Non-Hodgkin Lymphoma. <i>Clinical Nuclear Medicine</i> , 2016, 41, 169-172.	1.3	5
26	Early 18F-FDG uptake as a reliable imaging biomarker of T790M-mediated resistance but not MET amplification in non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors. <i>EJNMMI Research</i> , 2016, 6, 74.	2.5	7
27	Multimodal imaging with 18F-FDG-PET/CT and 111In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma. <i>Annals of Nuclear Medicine</i> , 2016, 30, 234-241.	2.2	11
28	Combined SPECT/CT and PET/CT for breast imaging. <i>Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment</i> , 2016, 809, 58-66.	1.6	14
29	18F-FDG PET/CT, 99mTc-MIBI, and MRI in the Prediction of Outcome of Patients With Multiple Myeloma. <i>Clinical Nuclear Medicine</i> , 2015, 40, 303-308.	1.3	30
30	Reversal of Warburg Effect and Reactivation of Oxidative Phosphorylation by Differential Inhibition of EGFR Signaling Pathways in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 5110-5120.	7.0	113
31	Monitoring Reversal of MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Using 3-Deoxy-3-[18F]-Fluorothymidine Positron Emission Tomography. <i>Clinical Cancer Research</i> , 2014, 20, 4806-4815.	7.0	24
32	Molecular imaging for detection of sensitivity and resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer. <i>Clinical and Translational Imaging</i> , 2014, 2, 43-53.	2.1	3
33	Radioiodide induces apoptosis in human thyroid tissue in culture. <i>Endocrine</i> , 2013, 44, 729-734.	2.3	9
34	Sphingosine Kinase 1 Overexpression Contributes to Cetuximab Resistance in Human Colorectal Cancer Models. <i>Clinical Cancer Research</i> , 2013, 19, 138-147.	7.0	87
35	Combined Imaging With 18F-FDG-PET/CT and 111In-Labeled Octreotide SPECT for Evaluation of Thymic Epithelial Tumors. <i>Clinical Nuclear Medicine</i> , 2013, 38, 354-358.	1.3	12
36	Metabolic Tumor Volume Assessed by ¹⁸ F-FDG PET/CT for the Prediction of Outcome in Patients with Multiple Myeloma. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1829-1835.	5.0	157

#	ARTICLE	IF	CITATIONS
37	³ â€²-Deoxy- ³ â€²- ¹⁸ F-Fluorothymidine PET/CT to Guide Therapy with Epidermal Growth Factor Receptor Antagonists and Bcl-x _L Inhibitors in Nonâ€“Small Cell Lung Cancer. Journal of Nuclear Medicine, 2012, 53, 443-450.	5.0	28
38	PET and SPECT in Cancer Theragnostics. , 2012, , 979-1014.		0
39	¹¹¹ In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1441-1448.	6.4	158
40	PET/CT in cancer research: from preclinical to clinical applications. Contrast Media and Molecular Imaging, 2010, 5, 190-200.	0.8	13
41	Imaging of ¹ ± ^v ²³ Expression by a Bifunctional Chimeric RGD Peptide not Cross-Reacting with ¹ ± ^v ²⁵ . Clinical Cancer Research, 2009, 15, 5224-5233.	7.0	46
42	Bone Scintigraphy and SPECT/CT in Bisphosphonate-Induced Osteonecrosis of the Jaw. Journal of Nuclear Medicine, 2009, 50, 1385.1-1385.	5.0	12
43	A new and selective radiolabeled ¹ ± ^v ²³ peptide antagonist as tracer in tumor diagnosis. Advances in Experimental Medicine and Biology, 2009, 611, 439-440.	1.6	0
44	¹⁸ F-FDG PET/CT, ^{99m} Tc-MIBI, and MRI in Evaluation of Patients with Multiple Myeloma. Journal of Nuclear Medicine, 2008, 49, 195-200.	5.0	155
45	Gefitinib Induction of <i>In vivo</i> Detectable Signals by Bcl-2/Bcl-xL Modulation of Inositol Triphosphate Receptor Type 3. Clinical Cancer Research, 2008, 14, 5209-5219.	7.0	25
46	^{99m} Tc-MIBI in the Evaluation of Breast Cancer Biology. , 2008, , 71-81.		0
47	Sestamibi and FDG-PET scans to support diagnosis of jaw osteonecrosis. Annals of Hematology, 2007, 86, 415-423.	1.8	60
48	Novel and Selective ¹ ± ^v ²³ Receptor Peptide Antagonist:Â Design, Synthesis, and Biological Behavior. Journal of Medicinal Chemistry, 2006, 49, 3416-3420.	6.4	32
49	Functional imaging of multidrug resistance in breast cancer. Physica Medica, 2006, 21, 24-27.	0.7	5
50	^{99m} Tc-sestaMIBI uptake in nonsecretory multiple myeloma. Hematology, 2005, 10, 335-338.	1.5	4
51	Technetium ^{99m} Sestamibi in Multiple Myeloma. Radiology, 2005, 234, 312-313.	7.3	4
52	Inhibition of Sp1 activity by a decoy PNAâ€“DNA chimera prevents urokinase receptor expression and migration of breast cancer cells. Biochemical Pharmacology, 2005, 70, 1277-1287.	4.4	26
53	Functional Imaging of Multidrug Resistant Phenotype by ^{99m} Tc-MIBI Scan in Patients with Multiple Myeloma. Cancer Biotherapy and Radiopharmaceuticals, 2004, 19, 165-170.	1.0	21
54	^{99m} Tc-MIBI in the evaluation of breast cancer biology. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, S88-S96.	6.4	60

#	ARTICLE	IF	CITATIONS
55	Bcl-2 overexpression prevents 99mTc-MIBI uptake in breast cancer cell lines. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 521-527.	6.4	23
56	Inhibition of early 99mTc-MIBI uptake by Bcl-2 anti-apoptotic protein overexpression in untreated breast carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 879-887.	6.4	30
57	Dynamic coupling of 99mTc-MIBI efflux and apoptotic pathway activation in untreated breast cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, 809-814.	6.4	16
58	Predictive value of technetium-99m sestamibi in patients with multiple myeloma and potential role in the follow-up. European Journal of Nuclear Medicine and Molecular Imaging, 2001, 28, 304-312.	2.1	25
59	Scintimammography with 99mTc-MIBI versus dynamic MRI for non-invasive characterization of breast masses. European Journal of Nuclear Medicine and Molecular Imaging, 2001, 28, 56-63.	2.1	27
60	Scintigraphic Detection of Multidrug Resistance in Cancer. Cancer Biotherapy and Radiopharmaceuticals, 2000, 15, 327-337.	1.0	31
61	Mucosal Expression of Carcinoembryonic Antigen and Carbohydrate Antigen 19-9 in Patients with Gastritis and Gastric Cancer. Cancer Detection and Prevention, 1999, 23, 116-122.	2.1	2
62	Tc-99m Sestamibi Scintigraphy in Multiple Myeloma. Clinical Nuclear Medicine, 1999, 24, 115-116.	1.3	4
63	Different patterns of technetium-99m sestamibi uptake in multiple myeloma. European Journal of Nuclear Medicine and Molecular Imaging, 1998, 25, 714-720.	6.4	68
64	Dynamic imaging: scintimammography. European Journal of Radiology, 1998, 27, S259-S264.	2.6	15
65	In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 1997, 24, 150-159.	2.1	150
66	In vitro receptor imaging for characterization of human solid tumors. Nuclear Medicine and Biology, 1994, 21, 771-774.	0.6	1
67	Cytosine arabinoside increases the binding of ¹²⁵ I-labelled epidermal growth factor and ¹²⁵ I-transferrin and enhances the in vitro targeting of human tumour cells with anti-(growth) Tj ETQq1 1 0.784314 rgBT 20 Overloc		
68	Endobronchial administration of iodine-131 B72.3 monoclonal antibody in patients with lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 1991, 18, 129-132.	2.1	1
69	Anti-murine antibody response to mouse monoclonal antibodies: Clinical findings and implications. International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology, 1989, 16, 121-125.	0.3	58
70	Tumor Imaging. , 0, , 277-309.		0
71	Non-invasive detection of epithelial mesenchymal transition phenotype and metastatic dissemination of lung cancer by liquid biopsy. Exploration of Targeted Anti-tumor Therapy, 0, , .	0.8	0